NCT04718792View on ClinicalTrials.gov

Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 9, 2023

Primary Completion Date

July 21, 2024

Study Completion Date

July 21, 2024

Conditions
Alcohol Use Disorder (AUD)
Interventions
DRUG

Psilocybin

A single administration of PEX010 (psilocybin 25 mg, opaque capsule for oral ingestion). PEX010 contains psilocybin (25 mg) naturally extracted from Psilocybe cubensis mushroom fruiting bodies, manufactured under current Good Manufacturing Practices (cGMP)

Trial Locations (1)

2000

Psychiatric Center Copenhagen, Copenhagen

All Listed Sponsors
collaborator

The Neurobiology Research Unit at Copenhagen University Hospital Rigshospitalet

UNKNOWN

lead

Anders Fink-Jensen, MD, DMSci

OTHER